文献速递皮肤肿瘤

黑色素瘤手术时机对生存的影响:基于国家癌症数据库的分析

Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.
PubMed 文献 · J Am Acad Dermatol · 2017-10-17

本研究利用美国国家癌症数据库(N=153,218)分析I-III期皮肤黑色素瘤患者从活检到 definitive 手术的时间对总生存的影响。多因素分析显示,全分期患者手术延迟超过90天与死亡风险升高相关;在I期亚组中,延迟30天以上即与死亡风险增加相关,而II-III期手术时机与生存无关。结论提示I期黑色素瘤应尽早手术。

要点

  • 全分期患者手术延迟≥90天死亡风险升高。
  • I期患者手术延迟≥30天即与死亡风险增加相关。
  • II-III期患者手术时机与生存无显著关联。

核心结论

  • I期黑色素瘤尽早手术与改善结局相关。
  • 全分期中手术延迟超过90天与死亡风险升高相关。

研究设计与样本

  • 基于美国国家癌症数据库(N=153,218)的回顾性队列研究。
  • 纳入I-III期皮肤黑色素瘤且有 definitive 手术时间和总生存数据的患者。
  • 采用t检验和卡方检验比较变量,Cox回归进行多因素分析。

主要发现

  • 全分期多因素分析中,活检后90-119天手术(HR 1.09;95%CI 1.01-1.18)和超过119天手术(HR 1.12;95%CI 1.02-1.22)较30天内手术死亡风险更高。
  • I期亚组中,活检后30-59天手术(HR 1.05;95%CI 1.01-1.1)、60-89天(HR 1.16;95%CI 1.07-1.25)、90-119天(HR 1.29;95%CI 1.12-1.48)和超过119天(HR 1.41;95%CI 1.21-1.65)死亡风险均升高。
  • II期和III期患者手术时机对生存无显著影响。

关键数值与推荐

  • 全分期:活检后90-119天手术HR 1.09(95%CI 1.01-1.18),超过119天HR 1.12(95%CI 1.02-1.22),参照为30天内手术。
  • I期:活检后30-59天HR 1.05(95%CI 1.01-1.1),60-89天HR 1.16(95%CI 1.07-1.25),90-119天HR 1.29(95%CI 1.12-1.48),超过119天HR 1.41(95%CI 1.21-1.65)。

临床怎么用

  • I期黑色素瘤患者应尽早安排 definitive 手术,避免不必要的延迟。
  • 对于II-III期患者,手术时机对生存影响不显著,但仍需结合临床情况决策。

局限性

  • 无法获得黑色素瘤特异性生存数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ideal timing for melanoma treatment, predominantly surgery, remains undetermined. Patient concern for receiving immediate treatment often exceeds surgeon or hospital availability, requiring establishment of a safe window for melanoma surgery. OBJECTIVE: To assess the impact of time to definitive melanoma surgery on overall survival. METHODS: Patients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (N = 153,218). The t test and chi-square test were used to compare variables. Cox regression was used for multivariate analysis. RESULTS: In a multivariate analysis of patients in all stages who were treated between 90 and 119 days after biopsy (hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.18) and more than 119 days (HR, 1.12; 95% CI, 1.02-1.22) had a higher risk for mortality compared with those treated within 30 days of biopsy. In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days (HR, 1.05; 95% CI, 1.01-1.1), 60 to 89 days (HR, 1.16; 95% CI, 1.07-1.25), 90 to 119 days (HR, 1.29; 95% CI, 1.12-1.48), and more than 119 days after biopsy (HR, 1.41; 95% CI, 1.21-1.65). Surgical timing did not affect survival in stages II and III. LIMITATIONS: Melanoma-specific survival was not available. CONCLUSION: Expeditious treatment of stage I melanoma is associated with improved outcomes.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Conic RZ, Cabrera CI, Khorana AA, et al. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. J Am Acad Dermatol. 2017. PMID: 29054718. doi:10.1016/j.jaad.2017.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。